Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy
Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy
复制标题
玻璃体内注射贝伐珠单抗治疗息肉状脉络膜血管病的渗出性分支血管网络
DOI：
10.1136/bjo.2011.204123
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Nishida K
中科院分区：
文献类型：
--
作者：
Wakabayashi T;Gomi F;Sawa M;Tsujikawa M;Nishida K
AimsTo评估玻璃体内贝伐单抗的长期疗效复发泄漏由于残留的分支血管网络在息肉状脉络膜血管病变后photodynamictherapy.MethodsForty 5眼渗出性分支血管网络与玻璃体内贝伐单抗治疗，并随访至少24个月。 所有患眼的原发性息肉样病变均已成功接受光动力疗法治疗。最佳矫正视力和视网膜形态学的变化进行了评估retrospectively.ResultsExudative分支血管网络的特点是隐匿性脉络膜新生血管（38只眼）或经典的脉络膜新生血管（7只眼）荧光血管造影。玻璃体内贝伐珠单抗在12个月内维持或改善了38只眼（84%）的视力，在24个月内维持或改善了36只眼（80%）的视力，尽管12个月和24个月时的平均视力与基线相比没有显著差异。 在24个月内，26只眼（58%）的黄斑积液持续完全消退。 16只眼（36%）对治疗有一次反应，但对复发性渗出的额外注射无反应。3只眼（7%）在整个随访期间对治疗无效。囊样黄斑水肿最终在10只眼睛和视力outcome.ConclusionIntravitreal贝伐单抗改善视网膜形态和维持视力超过1年，在大多数眼睛由于持续异常的血管网络息肉状脉络膜血管病变的复发性液体。 然而，治疗反应可能在第二年下降。
AimsTo assess the long-term efficacy of intravitreal bevacizumab for recurrent leakage owing to the residual branching vascular networks in polypoidal choroidal vasculopathy after photodynamic therapy.MethodsForty-five eyes with exudative branching vascular networks were treated with intravitreal bevacizumab and followed for at least 24 months. Original polypoidal lesions had been treated successfully with previous photodynamic therapy in all eyes. The best-corrected visual acuity and retinal morphological changes were assessed retrospectively.ResultsExudative branching vascular networks were characterised as occult choroidal neovascularisation (38 eyes) or classic choroidal neovascularisation (7 eyes) on fluorescein angiography. Intravitreal bevacizumab maintained or improved vision in 38 eyes (84%) over 12 months and in 36 eyes (80%) over 24 months, although the mean visual acuity at 12 and 24 months did not differ significantly compared with baseline. Complete resolution of macular fluid was achieved continuously in 26 eyes (58%) during 24 months. Sixteen eyes (36%) responded once to treatment but became unresponsive to additional injections for recurrent exudation. Three eyes (7%) were refractory to treatment throughout follow-up. Cystoid macular oedema eventually developed in 10 eyes and was a poor prognostic sign for visual outcome.ConclusionIntravitreal bevacizumab improved the retinal morphology and maintained vision over 1 year in most eyes with recurrent fluid owing to persistent abnormal vascular networks in polypoidal choroidal vasculopathy. The therapeutic response, however, may decrease during the second year.